Who are Sorafenib with Low-dose FP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sorafenib Tosylate Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sorafenib-with-low-dose-fp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Sorafenib with Low-dose FP — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sorafenib with Low-dose FP (Sorafenib with Low-dose FP) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-kinase inhibitor + chemotherapy combination. Area: Oncology.

phase 3 Multi-kinase inhibitor + chemotherapy combination RAF kinase, VEGFR, PDGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sorafenib with Low-dose FP (Sorafenib with Low-dose FP) — Ministry of Health, Labour and Welfare, Japan. Sorafenib is a multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, combined with low-dose fluoropyrimidine (FP) chemotherapy to enhance anti-tumor effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sorafenib with Low-dose FP TARGET	Sorafenib with Low-dose FP	Ministry of Health, Labour and Welfare, Japan	phase 3	Multi-kinase inhibitor + chemotherapy combination	RAF kinase, VEGFR, PDGFR
Sorafenib Tosylate Tablets	Sorafenib Tosylate Tablets	Beijing Shenogen Biomedical Co., Ltd	phase 3	multi-kinase inhibitor	RAF kinase, VEGFR, PDGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-kinase inhibitor + chemotherapy combination class)

Ministry of Health, Labour and Welfare, Japan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sorafenib with Low-dose FP — Competitive Intelligence Brief. https://druglandscape.com/ci/sorafenib-with-low-dose-fp. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab